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on consolidation CT. Thirteen trials used cisplatin+vinca alkaloid/eto-
poside, 1 used carboplatin+taxane, 2 used other platinum regimens, 
3 used vinca-alkaloid and 3 used other non platinum regimens. There 
was a signiﬁcant beneﬁt of sequential CT on survival (HR=0.88, 95% 
CI=[0.82-0.94], p=0.0001), with an absolute beneﬁt of 2.6% (from 
8.7% to 11.3%) at 3 years. There was no clear evidence of a difference 
in effect by type or timing of CT. Nor was there clear evidence that any 
patient subgroup deﬁned by age, sex, performance status, histology or 
stage beneﬁted more or less from sequential CT.
21 RCTs were eligible for the meta-analysis of concomitant CT. 
IPD was received from 15 RCTs (2733 patients) and only survival 
HR from one RCT (177 patients, IPD soon available). The survival 
analysis was based on these 16 trials and 2910 patients (87% of all 
known randomised patients). This adds 7 trials (1145 patients) to the 
previous analysis. The progression-free survival (PFS) analysis was 
based on 12 trials and 2034 patients. Median follow-up was 5.3 years. 
Nine trials used cisplatin or carboplatin alone, 3 used cisplatin or 
carboplatin+etoposide, 1 used carboplatin+taxane and 3 used taxane 
alone. In 4 trials, induction CT was added in both arms. There was 
a signiﬁcant beneﬁt of concomitant CT on survival (HR=0.88, 95% 
CI=[0.81-0.95], p=0.0008), with an absolute beneﬁt of 3.2% (from 
13.4% to 16.6%) at 3 years. Exclusion of trials with incomplete data 
did not change the results. There was a signiﬁcant beneﬁt of concomi-
tant CT on PFS (HR=0.81, 95% CI=[0.74-0.89], p<0.0001). There was 
no clear evidence that any patient subgroup beneﬁted more or less from 
concomitant CT.
Conclusions: These results demonstrate now a beneﬁt of sequential 
and concomitant CT in locally advanced NSCLC treated by RT. They 
provide robust estimates for future policies and research.
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Background: The previous IPD meta-analyses of CT in locally ad-
vanced NSCLC indicated that adding sequential CT to radiotherapy im-
proved survival (BMJ 1995;311:899) and that adding concomitant CT 
to radiotherapy could also improve survival (Ann Oncol 2006;17:473). 
The NSCLC Collaborative Group performed a meta-analysis of RCTs 
that compared concomitant RT-CT versus sequential RT-CT.
Methods: Systematic searches for RCTs were followed by the central 
collection, checking and re-analysis of updated IPD. Results from 
individual trials were combined using the stratiﬁed (by trial) log-rank 
test to calculate pooled hazard ratios (HRs). The primary outcome was 
overall survival, secondary outcomes were progression-free survival 
(PFS), cumulative incidences of loco-regional progression and of 
distant progression and acute toxicity (haematological, pulmonary, 
oesophageal).
Results: Seven trials which randomized 1,301 patients were eligible for 
the meta-analysis. IPD was received from 1,114 patients from 5 RCTs 
(86% of all known randomised patients). The HR for overall survival 
was also provided for one RCT (85 patients, IPD soon available). The 
main survival analysis was based on these 6 trials and 1,199 patients 
(92% of all randomized patients). Median follow-up was 5 years. The 
PFS analyses were based on the 5 trials with IPD. Two trials used same 
drugs and doses for concomitant and sequential CT. For sequential CT, 
all trials used at least cisplatin, induction CT was used in 5 trials and 
consolidation CT in one. For concomitant CT, cisplatin was used in 5 
trials with daily administration in 2 trials, and carboplatin was used in 
one trial. One trial used consolidation CT after concomitant CT. RT 
dose was lower than 60 Gy in 2 trials and RT was different between 
the two arms in one trial (same total dose but split course used in the 
concomitant arm).
Concomitant RT-CT increased acute oesophageal toxicity (grade 
3-4) from 3% to 18% with a relative risk of 5.7 (95% CI=[3.5-9.5], 
p<0.0001). There was no signiﬁcant difference between concomitant 
and sequential RT-CT for pulmonary acute toxicity. Haematological 
toxicity rates were highly variable among trials and the data were not 
pooled.
There was a signiﬁcant beneﬁt of concomitant RT-CT as compared 
to sequential RT-CT on survival (HR=0.83, 95% CI=[0.73-0.94], 
p=0.0026), with an absolute beneﬁt of 6.6% (from 18.2% with sequen-
tial RT-CT to 24.8% with concomitant RT-CT) at 3 years. For progres-
sion-free survival, the HR was 0.89 (95% CI=[0.78-1.00], p=0.0585). 
Concomitant CT decreased loco-regional progression (HR=0.76, 95% 
CI=[0.62-0.94], p=0.011), but its effect was not different from that of 
sequential CT on distant progression (HR=1.04, 95% CI=[0.86-1.25], 
p=0.669). There was no clear evidence of a difference in effect by type 
of CT. Nor was there clear evidence that any patient subgroup deﬁned 
by age, sex, performance status, histology or stage beneﬁted more or 
less from concomitant CT. 
Conclusions: Concomitant RT-CT, as compared to sequential RT-
CT, improved survival of patients with locally advanced NSCLC, 
mainly due to the decrease of loco-regional progression, at the cost of 
increased acute oesophageal toxicity.
Unrestricted grants from French PHRC, LNCC and Sanoﬁ-Aventis
A1-06 Combined Modality Therapy in NSCLC I, Mon, 13:45 - 15:30
Randomized multicenter german trial of surgery plus radiotherapy 
versus tri-modality treatment of operable stage IIIA NSCLC - long-
term follow-up results
Eberhardt, Wilfried E.1 Korfee, Sönke1 Pöttgen, Christoph2 Wagner, 
Horst3 Gauler, Thomas1 Passlick, Bernward4 Stamatis, Georgios5 von 
Pawel, Joachim3 Budach, Volker6 Wilke, Hansjochen7 Stuschke, Martin2 
1 Dept. of Internal Medicine (Cancer Res.), West German Cancer 
Centre, University Hospital of the University of Duisburg-Essen, Essen, 
Germany 2 Dept. of Radiation Therapy, West German Cancer Cen-
tre, Essen, Germany 3 Asklepios Klinik Gauting, Gauting, Germany 4 
Clinics for Thoracic Surgery, University Hopital, Freiburg, Germany 
Copyright © 2007 by the International Association for the Study of Lung Cancer S311
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
5 Dept. of Thoracic Endoscopy and Thoracic Surgery, Ruhrlandklinik 
Essen-Heidhausen, Essen, Germany 6 Clinic for Radiation Oncology, 
Charite Campus-Mitte, Berlin, Germany 7 Kliniken Essen-Mitte; Huys-
sen-Stiftung, Essen, Germany 
Rationale: 1994, selected patients(pts) early stage IIIA-NSCLC 
(operable, 1-2 LN involved at mediastinoscopy, no clinical N2, no 
bulky/extranodal disease) were taken to upfront surgery(S) at centers 
in Europe/North America. We compared this approach to aggressive 
tri-modality therapy - induction chemotherapy(CTx), preoperative 
radiochemotherapy(RTx/CTx) and deﬁnitive S - in a multicenter ran-
domized GERMAN KREBSHILFE trial (full trials grant).
Patients and Methods: operable IIIA pts (criteria above, mediasti-
noscopy, central T3N0-1, WHO 0,1) stratiﬁed (TN-group, center) and 
randomized: arm A - S and postoperative RTx (50-60 Gy); arm B - in-
duction CTx (3 x cisplatin(P) 60 mg/m2 d 1+7/etoposide(E) 150 mg/m2 
d 3,4,5) + concurrent RTx/CTx (45 Gy; 1.5 Gy bid; 1 x P 50 mg/m2 d 2 
+ 9, E 100 mg/m2 d 4,5,6) + S (+ prophylactic cranial irradiation (PCI) 
- 15 x 2 Gy = 30 Gy in 3 wks) (preliminary data: Eberhardt et al, Lung 
Cancer 2003;41:S63(O-213), Suppl 2).
Results: 11/94 to 7/01 112 pts randomized. 6 pts (3/arm) not eligible 
(misstaging, pts refusal, early progression prior any study therapy). 106 
pts eligible for complete analysis 3/2007: Pts characteristics M 90 F 16; 
age median (med) 59 (37-71); SCC 55 adeno-ca 35 LCC 16; A: n = 51 
pts T3N0-1 3 T1-2N2 38 T3N2 10; B: n = 55 pts T3N0-1 3 T1-2N2 45 
T3N2 7. A: S 50/50 probatory thoracotomy (PT) 5/50 R1/2 10/50 com-
plete resection (R0) 35/50; B: S 39/54 PT 1/54 R1/2 6/54 R0 32/54; 
peri- and postoperative morbidity/mortality not signiﬁcantly different 
between A/B (rate of early postoperative deaths, infections, stump 
insufﬁciencies, bleeding, embolisms, postop duration of hospitalization, 
time on postop respirator, time on ICU). Strong trend for more limited 
surgical resections following induction: number of pneumonectomies: 
A 22,B 11. Although terminated early due to slow accrual/emerging 
data for adjuvant CTx(IALT), the survival(surv) results as follows: 
median(med) overall surv: A 15 mo vs B 29 mo (p = 0.15 Wilcoxon 
W); med event-free surv: 9 mo vs 15 mo (p = 0.12 W); med disease 
speciﬁc(spec) surv 10 mo vs 18 mo ( p = 0.026 W). 5-year overall surv 
18% vs 16%; event-free surv: 20% vs 24%; disease spec surv 23% vs 
24%. Beyond 3 yrs from randomization intercurrent events (co-mor-
bidities) and second cancers predominant reason for deaths. Med surv 
of pts still alive 3/07: 94 mo(n = 14,73+-149+). 
Conclusion: This tri-modality protocol was feasible/safe in the mul-
ticenter setting. S following complex bi-modality induction did not 
show increased morbidity/mortality. Strong trend towards lung-sparing 
surgery in the arm with preoperative complex induction (down-staging? 
organ-sparing effect?). Results of this trial mandate rate of less exten-
sive S interventions (eg. lobectomies) as further important endpoint to 
be added within clinical trials of comparable pts populations (signiﬁ-
cant risk for pneumonectomy at thoracotomy). Although surv data 
favoured tri-modality in the ﬁrst four yrs - overall no of pts randomized 
does not allow valid conclusions concerning this endpoint. Currently, 
data on brain-relapse -free surv are analyzed with different policy for 
PCI in both arms (PCI vs no PCI). 
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Background: Surgical resection in patients with stage IIIA-pN2 
NSCLC is usually reserved for patients with downstaging of medi-
astinal lymph nodes (LNs) after induction therapy. However, clinical 
restaging after induction therapy is often inaccurate. Moreover, there 
are insufﬁcient data to exclude all patients with persistent mediastinal 
disease from surgery. Assuming baseline endoscopic mediastinal stag-
ing in the near future, we explored a restaging strategy combining tis-
sue analysis of mediastinal LNs obtained post-induction, and FDG-PET 
for monitoring response in the primary tumour.
Methods: Baseline and repeat PET after three cycles of induc-
tion chemotherapy, as well as complete resection specimens of both 
mediastinal LNs and primary tumour, were available in 30 patients 
out of our prospective database of surgical multimodality therapy in 
IIIA-pN2 NSCLC patients (period: 04-1995 to 06-2002; ref. Lorent et 
al, Ann Oncol 15:1645, 2004). In these 30 patients, histological tumour 
grading of both LNs and primary tumour was performed by means 
of conventional morphometric procedures based on a point counting 
technique, as described by Gundersen (ref. Gundersen et al, APMIS 
96:379, 1988). Three morphometric grading groups were considered: 
mediastinal downstaging (clearance of mediastinal disease), ‘minor’ 
residual mediastinal disease (<10% viable tumour cells) and ‘major’ 
residual mediastinal disease (>10% viable tumour cells). These medias-
tinal morphometric grading groups, together with the percent decrease 
of SUVmax of the primary tumour, were correlated with survival to 
establish an algorithm for prognostic restaging.
Results: The median and 5-year overall survival for the 30 patients was 
36.4 months and 30%, respectively. The median decrease of SUVmax 
on the primary tumour between baseline and repeat PET scan was 
60%, and this value was used as cut-off. A >60% decrease compared 
to a <60% decrease of SUVmax resulted in a median survival time of 
57.5 versus 18.3 months and 5-year overall survival 47% versus 13%, 
respectively; log-rank p=0.01, HR 0.34 (95%CI 0.12-0.74). No patient 
with ‘major’ residual mediastinal disease survived 5 years, while 5-year 
overall survival was 43% both in patients with mediastinal clearance as 
well as in those with ‘minor’ residual mediastinal disease. Combined 
prognostic stratiﬁcation resulted in two subgroups: patients with down-
staging or persistent ‘minor’ mediastinal LN involvement and >60% 
decrease of SUVmax on the primary tumour were allocated as ‘Good 
Prognosis group’ (n=13). Patients with downstaging or persistent 
‘minor’ mediastinal LN involvement and <60% decrease of SUVmax 
on the primary tumour were pooled with patients having persistent 
‘major’ mediastinal LN involvement and allocated as ‘Poor Prognosis 
group’ (n=17). The median and 5-year overall survival for these Good 
and Poor Prognosis groups were “not reached” versus 18.3 months, 
and 62% versus 6%, respectively; log-rank p<0.0001, HR 0.18 (95%CI 
0.06-0.38). 
